Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Scoring/Classifying Patients With Advanced HCC

September 3rd 2021

Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.

Dr. Chiorean on the Role of Molecular Testing in Pancreatic Cancer

September 2nd 2021

E. Gabriela Chiorean, MD, discusses the role of molecular testing in pancreatic cancer.

Neoadjuvant Cabozantinib/Nivolumab Leads to Improved Resection Rates in HCC

September 2nd 2021

The combination of cabozantinib and nivolumab as a neoadjuvant regimen led to encouraging margin-negative resection and major pathological response rates in patients with hepatocellular carcinoma, according to results of a single-arm, phase 1b study that were published in Nature Cancer.

FDA Grants Orphan Drug Status to Gavocabtagene Autoleucel for Cholangiocarcinoma

September 2nd 2021

The FDA has granted an orphan drug designation to gavocabtagene autoleucel as a potential treatment for patients with cholangiocarcinoma.

Adjuvant Treatment Advances in Operable HCC

August 27th 2021

Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.

Hepatic Arterial Infusion Chemotherapy for HCC

August 27th 2021

Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.

FDA Approval Insights: Nivolumab Plus Chemo for Frontline Gastric Cancer

August 26th 2021

Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, key findings from the pivotal CheckMate-649 trial, and future directions with immunotherapy in the field.

FDA Green Lights Companion Diagnostic for Ivosidenib in IDH1-Mutant Cholangiocarcinoma

August 26th 2021

The FDA has approved the Oncomine Dx Target Test, developed by Thermo Fisher Scientific, for use as a companion diagnostic to identify patients with IDH1-mutated cholangiocarcinoma who may be eligible to receive the newly approved IDH1 inhibitor ivosidenib.

FDA Approves Ivosidenib for IDH1-Mutated Cholangiocarcinoma

August 25th 2021

The FDA has approved ivosidenib for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation, as detected by an FDA-approved test.

Phase 2 Trial of Bintrafusp Alfa in Frontline Biliary Tract Cancer Discontinued

August 24th 2021

Merck KGaA, Darmstadt, Germany has decided to discontinue the phase 2 INTR@PID BTC 055 trial examining bintrafusp alfa plus gemcitabine and cisplatin in the frontline treatment of patients with locally advanced or metastatic biliary tract cancer.

Novel Approaches Under Study for Metastatic CRC

August 24th 2021

John L. Marshall, MD; Marwan G. Fakih, MD; and Joleen M. Hubbard, MD, highlight novel strategies in the metastatic colorectal cancer pipeline that look exciting and consider their integration into future clinical practice.

Treating Metastatic CRC With TKI/I-O Combinations

August 24th 2021

The rationale for continuing to study the combination of immunotherapies with novel tyrosine kinase inhibitors in metastatic colorectal cancer.

Pancreatic Cancer “Evangelist” Collaborates to Save Lives

August 23rd 2021

If there is one touchstone that emerges from Dr. Margaret A. Tempero's career of studying and treating pancreatic cancer, it is her persistence in simply trying to help her patients.

Neoadjuvant Therapy to Downstage HCC

August 20th 2021

Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.

Advances in Locoregional Therapy for Early Stage HCC

August 20th 2021

University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.

FDA Grants Orphan Drug Status to LP-184 for Pancreatic Cancer

August 17th 2021

The FDA has granted an orphan drug designation to LP-184 as a potential therapeutic option for patients with pancreatic cancer.

EMA Validates Applications for Nivolumab/Ipilimumab, Nivolumab/Chemo in Frontline ESCC

August 17th 2021

The European Medicines Agency has validated its Type II Variation Marketing Authorization Applications for nivolumab plus ipilimumab and nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy as frontline options for adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

Metastatic CRC: Pembrolizumab Plus Lenvatinib

August 17th 2021

Implications for using the combination of pembrolizumab and lenvatinib to treat patients with metastatic colorectal cancer based on updated data from the LEAP-005 study.

Metastatic CRC: Nivolumab Plus Regorafenib

August 17th 2021

Considerations for treating patients with metastatic colorectal cancer with the combination of nivolumab and regorafenib based on preliminary data.

Sintilimab/Chemo Improves OS in Frontline Advanced or Metastatic Gastric or GEJ Adenocarcinoma

August 16th 2021

Sintilimab plus oxaliplatin/capecitabine significantly improved overall survival over chemotherapy alone when used as a first-line treatment in patients with unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.